Compare Sunbelt Rentals Holdings Inc. Common Stock (SUNB) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sunbelt Rentals Holdings Inc. Common Stock vs Travere Therapeutics Inc. Common Stock — how do they compare? Sunbelt Rentals Holdings Inc. Common Stock trades at $75.04 (market cap $31.69B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Sunbelt Rentals Holdings Inc. Common Stock is far larger — about 6.5× Travere Therapeutics Inc. Common Stock's market cap, and Sunbelt Rentals Holdings Inc. Common Stock pays a 1.36% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Sunbelt Rentals Holdings Inc. Common Stock for 6 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| SUNB | TVTX | |
|---|---|---|
Market Cap | $31.69B | $4.88B |
Volume | 3,330,792 | 1,668,577 |
Sector | Industrials | Health |
52-Week High | $86.06 | $67.52 |
52-Week Low | $63.09 | $26.79 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $43.08B | $5.01B |
Dividend Yield | 1.36% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SUNB trades at $77.33, up 2.34% with neutral technical signals. The company reported strong Q2 2026 earnings beat ($1.18 vs $0.99 expected) and raised FY2027 guidance. Valuation metrics show P/E of 23.08 and ROE of 18.37%, with revenue growth from $10.79B to $11.5B projected. Recent institutional buying includes State Street Corp's $441M investment in Q2 2026.
Outlook remains positive with analyst consensus target of $86.83 (12.3% upside). Key opportunities include infrastructure demand and specialty equipment rental growth, while risks involve significant debt load ($7.5B) and declining free cash flow. The stock presents a balanced risk-reward profile with moderate growth potential.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Sunbelt Rentals Holdings Inc. Common Stock
Sunbelt Rentals provides equipment rentals and related services in the United States, Canada, and the United Kingdom. Its fleet includes general and specialty equipment for construction, industrial, infrastructure, and maintenance projects.
Read more on SUNB →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
